Combined use of interferon alpha-1b, interleukin-2, and thalidomide to reverse the AML1-ETO fusion gene in acute myeloid leukemia

This study aims to explore the effect of the ITI (interferon alpha-1b, thalidomide, and interleukin-2) regimen on the AML1-ETO fusion gene in patients with t(8;21) acute myeloid leukemia (AML) who were in hematologic remission but positive for the AML1-ETO fusion gene. From September 2014 to Novembe...

Descripción completa

Detalles Bibliográficos
Autores principales: Mi, Ruihua, Chen, Lin, Yang, Haiping, Zhang, Yan, Liu, Jia, Yin, Qingsong, Wei, Xudong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440286/
https://www.ncbi.nlm.nih.gov/pubmed/34312685
http://dx.doi.org/10.1007/s00277-021-04621-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440286/
https://www.ncbi.nlm.nih.gov/pubmed/34312685
http://dx.doi.org/10.1007/s00277-021-04621-w

Ejemplares similares